Margarida Maia, PhD, science writer —

People with cystic fibrosis (CF) who carry two disease-causing F508del mutations and those who have had no prior treatment with CFTR modulators are up to five times more likely to see greater improvement of sinonasal symptoms after starting highly effective modulator treatment, a study found. An improvement of…

Younger adults with cystic fibrosis (CF) and a history of frequent pulmonary exacerbations are more likely than other adult patients to have put on weight six months into treatment with Trikafta (ivacaftor/tezacaftor/elexacaftor), a study found. The study, “Predicting weight gain in patients with cystic fibrosis on triple…

Treatment with the antibiotic azithromycin reduces abnormal thickening of the walls of bronchi — air passages leading to the lungs — in young children with cystic fibrosis (CF), and this may translate into smoother blood flow to the lungs, a study suggests. Data come from COMBAT-CF (NCT01270074),…

Treatment with Kaftrio (elexacaftor, tezacaftor, and ivacaftor), sold as Trikafta in the U.S., may save people with cystic fibrosis (CF) an average of 15 minutes each day of respiratory physiotherapy to help with breathing, a study has found. The study, “Perceived burden of respiratory physiotherapy in people with…

Highly effective CFTR modulators, which target the cause of cystic fibrosis (CF), may ease signs of low iron levels in some patients with the disease, but low iron levels may remain even with treatment with the medications, a study finds. The scientists also emphasized that people with CF who…

Abnormal glucose tolerance is common in young cystic fibrosis (CF) patients. Early screening, starting at the age of 5, may lead to better health outcomes by making it possible to intervene early, a meta-analysis study found. “Abnormal glucose tolerance affects every third child” and “every second adult” with CF,…

The Cystic Fibrosis Foundation (CFF) has invested another $5 million into BiomX, which will help fund a Phase 2b clinical trial of BX004 — a phage therapy the company is developing to clear up lung infections in cystic fibrosis (CF) caused by the Pseudomonas aeruginosa bacteria. In…

Sotagliflozin, an oral medication approved in the U.S. under the brand name Inpefa as a broadly used treatment for heart failure, may ease symptoms of liver disease related to cystic fibrosis (CF), according to a study in rabbits. While it’s still too early to tell if sotagliflozin will…

Some people with cystic fibrosis (CF) have levels of sweat chloride above the cut-off for a diagnosis of the disease despite being on CFTR modulators, suggesting there is room for improving treatment, a study found. The study, “Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with…

BiomX and Adaptive Phage Therapeutics (APT) are entering into a merger agreement with a goal of pooling resources to advance phage therapies such as BX004 — an experimental cystic fibrosis (CF) treatment that aims to clear up lung infections caused by Pseudomonas aeruginosa bacteria. At the same time as…